Carolyn Owen, Versha Banerji, Nathalie Johnson, Alina Gerrie, Andrew Aw, Christine Chen, Sue Robinson
No abstract text is available yet for this article.
April 3, 2023: Leukemia Research
Howard Lopes Ribeiro Junior, Paola Gyuliane Gonçalves, Daniel Antunes Moreno, João Vitor Caetano Goes, Roberta Taiane Germano de Oliveira, Carlos Victor Montefusco-Pereira, Tatiana Takahasi Komoto, Ronald Feitosa Pinheiro
Differentially expressed genes (DEGs) biomarkers can be used to help diagnose and monitor the disease, as well as to determine which treatments are most effective. So, given the complexity of Myelodysplastic neoplasm (MDS), it is difficult to determine the impact and disparities of DEGs between CD34+ HSC (hematopoietic stem cells) or primary bone marrow cells (PBMC) in MDS pathogenesis, and therefore it remains largely unknown. Here, we performed an in-silico transcriptome analysis on CD34+ HSC and PBMC from 1092 MDS patients analyzing the divergences between differential gene expression patterns in these two cell types as potential pathogenic biomarkers for MDS...
March 29, 2023: Leukemia Research
Jeremiah E Moore, Paige C Bloom, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Sally A Quataert, Timothy R Mosmann, Ronald P Taylor, Danielle S Wallace, Michael R Elliott, Paul M Barr, Clive S Zent
Monoclonal antibody induced infusion reactions (IRs) can be serious and even fatal. We used clinical data and blood samples from 37 treatment naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) initiating therapy for progressive disease with a single 50 mg dose of intravenous (IV) rituximab at 25 mg/h. Twenty-four (65 %) patients had IRs at a median of 78 min (range 35-128) and rituximab dose of 32 mg (range 15-50). IR risk did not correlate with patient or CLL characteristics, CLL counts or CD20 levels, or serum rituximab or complement concentrations...
March 29, 2023: Leukemia Research
Eun Sang Yi, Hee Jo Baek, Hee Young Ju, Seong Koo Kim, Jae Wook Lee, Bin Cho, Bo Kyung Kim, Hyoung Jin Kang, Hoon Kook, Eu Jeen Yang, Young Tak Lim, Won Kee Ahn, Seung Min Hahn, Sang Kyu Park, Eun Sun Yoo, Keon Hee Yoo
Juvenile myelomonocytic leukemia (JMML) is a life-threatening myeloproliferative neoplasm. The chemotherapeutic effect on survival remains unclear, and feasible standardized response criteria are yet to be established. We aimed to evaluate the chemotherapeutic response and its effect on survival in patients with JMML. A retrospective registry was reviewed for children diagnosed with JMML between 2000 and 2019. Response was assessed according to the criteria proposed by the International JMML Symposium in 2007 (criteria I) and the updated version in 2013 with its modifications (criteria II)...
March 28, 2023: Leukemia Research
Mario Delia, Vito Pier Gagliardi, Paola Carluccio, Immacolata Attolico, Corinne Contento, Daniela Di Gennaro, Francesco Albano, Pellegrino Musto
No abstract text is available yet for this article.
March 24, 2023: Leukemia Research
Shana Chen, Yonghong Tao, Qian Wang, Jun Ren, Yipei Jing, Junpeng Huang, Ling Zhang, Rufei Li
Multiple studies have demonstrated that excessive glucose utilization is a common feature of cancer cells to support malignant phenotype. Acute myeloid leukemia (AML) is recognized as a heterogeneous disorder of hematopoietic stem cells characterized by altered glucose metabolism. However, the role of glucose metabolic dysfunction in AML development remains obscure. In this study, glucose and 2-Deoxy-D-glucose (2-DG) treatment were applied to analyze the relationship between glucose metabolism and cell survival...
March 22, 2023: Leukemia Research
S P Chantepie, J B Mear, A R Briant, J P Vilque, A C Gac, S Cheze, S Girault, P Turlure, J P Marolleau, D Lebon, A Charbonnier, F Jardin, P Lenain, L Peyro-Saint-Paul, V Abonnet, J J Dutheil, Y Chene, A Bazin, O Reman, J J Parienti
BACKGROUND: Retrospective studies in hematological unit have suggested that single red blood cell (1-RBC) unit transfusion policy may reduce the number of RBC used without negative clinical impact. METHOD: Acute leukemia patients requiring intensive chemotherapy or patients receiving autologous or allogeneic transplantation were randomly assigned to receive either single RBC (1-RBC arm) or double RBC (2-RBC arm) per transfusion with a hemoglobin trigger of 8 g/dL...
March 18, 2023: Leukemia Research
Yusuke Terao, Yasuhide Nakayama, Masahiro Abo, Yuhei Otobe, Mizue Suzuki, Shingo Koyama, Shu Tanaka, Iwao Kojima, Naoto Haga, Minoru Yamada
INTRODUCTION: Poor skeletal muscle function is relatively high in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), leading to various negative health outcomes. This study aimed to investigate the relationship between the quantity and quality of skeletal muscle before transplantation and the short-to long-term survival after transplantation in patients undergoing allo-HSCT. METHODS: This retrospective cohort study included 156 patients undergoing allo-HSCT (men, 67...
March 16, 2023: Leukemia Research
Tine Bichel Lauritsen, Jan Maxwell Nørgaard, Susanne Oksbjerg Dalton, Kirsten Grønbæk, Tarec Christoffer El-Galaly, Lene Sofie Granfeldt Østgård
Further temporal data on incidence, treatment patterns, and prognosis for patients with myelodysplastic syndromes (MDS) are needed. This study examined 10-year trends in incidence, treatment patterns, and all-cause mortality in a population-based cohort of 2309 MDS patients using Danish nationwide registries (2010-2019). We computed annual incidence rates overall and according to sex and age-groups. We examined temporal changes in the cumulative incidence of MDS specific treatments initiated within one year from diagnosis and temporal changes in the absolute risk of death and five-year adjusted hazard ratios (aHRs) for death, adjusting for age, sex and comorbidity...
March 10, 2023: Leukemia Research
Michel Delforge, Paula Rodríguez Otero, Nina Shah, Olga Moshkovich, Julia Braverman, Devender S Dhanda, Sally Lanar, Jennifer Devlen, Matthew Miera, Heather Gerould, Timothy B Campbell, Nikhil C Munshi
OBJECTIVE: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial. METHODS: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored patient perceptions of ide-cel treatment experience, advantages and disadvantages, and long-term health-related quality of life impact...
June 2023: Leukemia Research
Carmelo Gurnari, Valeria Visconte
Clonal hematopoiesis (CH) is a result of the selective expansion of hematopoietic stem and progenitor cells (HSPCs) carrying somatic mutations originating from a primary HSC. The advent of modern genomic technologies has helped recognizing that CH is common in elderly healthy subjects as a result of the aging bone marrow (BM). CH in healthy subjects without abnormalities in blood counts is known as CH of indeterminate potential. CH is also seen in BM failure (BMF) disorders. Whether CH alarms for the risk to develop malignant evolution in BMF or creates an adaptation to selective pressure is a matter of controversy...
April 2023: Leukemia Research
Montserrat Miret, Amanda Anderson, Pooja Hindocha, Lorena Cirneanu, Christina Lymperopoulou, Emanuil Markov, William Kizito, Ferdinando Emanuele Vegni
BACKGROUND: Treatments for relapsed/refractory (r/r) B-cell non-Hodgkin's lymphoma (NHL) may be associated with an increased risk of second primary malignancies (SPMs). Currently available SPM incidence benchmarks are unreliable due to small sample sizes. METHODS: The Cancer Analysis System (CAS), a population-level cancer database in England, was used to identify patients with incident B-cell NHL diagnosed during 2013-2018 with evidence of r/r disease. Incidence rates (IRs) of SPMs after r/r disease diagnosis were calculated per 1000 person-years (PYs) and stratified by age, sex, and SPM type...
April 2023: Leukemia Research
L Maurillo, A Spagnoli, A Candoni, C Papayannidis, E Borlenghi, D Lazzarotto, L Fianchi, M Sciumè, M E Zannier, F Buccisano, M I Del Principe, V Mancini, M Breccia, R Fanin, E Todisco, M Lunghi, R Palmieri, N Fracchiolla, P Musto, G Rossi, A Venditti
We compared the efficacy of azacitidine (AZA) and decitabine (DEC) in elderly patients with untreated AML, diagnosed according to WHO criteria. In the two groups, we evaluated complete remission (CR), overall survival (OS) and disease free survival (DFS). The AZA and DEC groups included 139 and 186 patients, respectively. To minimize the effects of treatment selection bias, adjustments were made using the propensity-score matching method, which yielded 136 patient pairs. In the AZA and DEC cohort, median age was 75 years in both, (IQR, 71-78 and 71-77), median WBCc at treatment onset 2...
April 2023: Leukemia Research
Raveen Stephen Stallon Illangeswaran, Daniel Zechariah Paul Jebanesan, Kezia Kanimozhi Sivakumar, Rakhi Thalayattu Vidhyadharan, Bharathi M Rajamani, Nancy Beryl Janet, Ernest David, Shaji Ramachandran Velayudhan, Vikram Mathews, Poonkuzhali Balasubramanian
Chemotherapy resistance leading to disease relapse is a significant barrier in treating acute myeloid leukemia (AML). Metabolic adaptations have been shown to contribute to therapy resistance. However, little is known about whether specific therapies cause specific metabolic changes. We established cytarabine-resistant (AraC-R) and Arsenic trioxide-resistant (ATO-R) AML cell lines, displaying distinct cell surface expression and cytogenetic abnormalities. Transcriptomic analysis revealed a significant difference in the expression profiles of ATO-R and AraC-R cells...
March 3, 2023: Leukemia Research
William J Archibald, Andrea M Baran, AnnaLynn M Williams, Rabih M Salloum, W Richard Burack, Andrew G Evans, Chauncey R Syposs, Clive S Zent
INTRODUCTION: Splenic B-cell lymphomas are rare and understudied entities. Splenectomy is frequently required for specific pathological diagnosis in patients with splenic B-cell lymphomas other than classical hairy cell leukemia (cHCL), and can be effective and durable therapy. Our study investigated the diagnostic and therapeutic role of splenectomy for non-cHCL indolent splenic B-cell lymphomas. METHODS: Observational study of patients with non-cHCL splenic B-cell lymphoma undergoing splenectomy between 1 August 2011 and 1 August 2021 at the University of Rochester Medical Center...
March 2, 2023: Leukemia Research
Ebru Kilic Gunes, Zubeyde Nur Ozkurt, Seyma Yildiz, Gulsum Ozet, Funda Ceran, Murat Albayrak, Merih Reis Aras, Tuba Bulduk, Selim Sayin, Meltem Ayli
Maintenance therapy in APL is still a standard especially in high-risk patients treated with chemotherapy+ATRA combination whereas the role of the maintenance therapy in low-risk patients is controversial. This study aims to compare the efficacy and toxicity of ATRA monotherapy and ATRA+MTX+ 6-MP combination as the maintenance treatment for 2 years in APL patients who achieved molecular complete response after induction and consolidation with ATRA+chemotherapy. A total of 71 patients from 4 different centers were included in this study...
March 2, 2023: Leukemia Research
Aubrey K Hubbard, Derek W Brown, Mitchell J Machiela
Mosaic chromosomal alterations (mCAs) are the clonal expansion of large somatically acquired structural chromosomal changes present on the autosomes and sex chromosomes. Most studies of mCAs use existing genotype array intensity data from large populations to investigate potential risk factors and disease outcomes associated with mCAs. In this review, we perform a comprehensive examination of existing evidence for mCA disease and mortality associations and provide a framework for interpreting these associations in the context of important biases specific to mCA studies...
March 2023: Leukemia Research
Pavel Jindra, Michal Karas, Daniel Lysák, Jiří Šrámek, Kateřina Steinerová, Marcela Hrabětová, Alexandra Jungová
BACKGROUND: Older patients with AML/MDS have a poor prognosis with alloHCT as the only curative option. However alloHCT is challenging given its high TRM. Recently, a composite endpoint of GRFS was proposed to define transplant success. A single centre retrospective analysis was performed to determine the main variables influencing GRFS. PATIENTS AND METHODSMETHODS: 91 consecutive patients≥ 60 years (median 64 years, range 60-74) with AML/MDS who received reduced-intensity alloHCT during 2001-2017 analysed...
February 24, 2023: Leukemia Research
Alex Bataller, Kelly S Chien, Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Samuel Urrutia, Emmanuel Almanza-Huante, Georgina Gener-Ricos, Farhad Ravandi, Elias Jabbour, Tapan Kadia, Gautam Borthakur, Guillermo Garcia-Manero
No abstract text is available yet for this article.
February 15, 2023: Leukemia Research
Tugcan Alp Kirkizlar, Onur Kirkizlar, Ufuk Demirci, Aytug Umut, Huseyin Iflazoglu, Elif Gulsum Umit, Ahmet Muzaffer Demir
OBJECTIVE: Hypomethylating agents may have adverse effects such as cytopenias, cytopenia associated infections and fatality due to infections despite their favorable effects in the treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). The infection prophylaxis approach is based on expert opinions and real-life experiences. Hence, we aimed to reveal the frequence of infections, predisposing factors of infection and to analyse infection attributable mortality in patients with high-risk MDS, CMML and AML who received hypomethylating agents in our center where routine infection prophylaxis is not applied...
February 15, 2023: Leukemia Research
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.